Intratumor Application of Human Leukocyte Interferon-α in Patients with Malignant Brain Tumors

Jereb, Berta; Petric, J.; Lamovec, Janez; Škrbec, Miha; Šošš, Evgen

doi:10.1097/00000421-198902000-00001

Cited by 21 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IFN- treatment of patients with malignant gliomas showed positive results in some clinical trials [49][50][51] but not in others [52,53]. The results from the use of IFN- in these kinds of patients were expected with interest, because the immune-suppression is one of the principal characteristics of these patients.…”

Section: Discussionmentioning

confidence: 99%

CIGB-128, as compassionate intracranial treatment in patients with non-operable or progressive high grade gliomas

Garcia-Vega¹,

Salva-Camaño²,

García-Iglesias³

et al. 2015

J Cancer Res Ther.

View full text Add to dashboard Cite

IFNs are a family of natural multifunctional glycoproteins with a multitude of antitumor effects including inhibition of cell proliferation, induction of cell differentiation, upregulation of class I major histocompatibility complex antigens, inhibition of angiogenesis, and establishment of a T-helper 1 (Th1) type response [1, 2]. IFN- sensitizes human malignant glioma cells to CD95Linduced apoptosis [3] down-regulates the expression of the proangiogenic molecules, such as basic fibroblast growth factor (bFGF), IL-8, and matrix metalloproteinase (MMP)-2 and-9 and inhibits the motility of vascular endothelial cells in vitro and angiogenesis in vivo [4]. IFN- has strong anti-proliferative effects in glioblastoma cell lines and in vivo glioma cells expression of IFN- result in a significant inhibition of tumor growth [5, 6]. IFN- upregulates several mediators of apoptosis in astrocitomas

show abstract

Section: Discussionmentioning

confidence: 99%

CIGB-128, as compassionate intracranial treatment in patients with non-operable or progressive high grade gliomas

Garcia-Vega¹,

Salva-Camaño²,

García-Iglesias³

et al. 2015

J Cancer Res Ther.

View full text Add to dashboard Cite

show abstract

“…Intratumoral injection of IFN-α was the first such trial to be undertaken (Jereb et al 1989;Farkkila et al 1994). Given the various pro-inflammatory cytokines that are downregulated in gliomas, the thought arose that infusing glioma patients with these cytokines would induce an immune reaction that would subsequently eradicate the tumor.…”

Section: Systemic Immunosuppressionmentioning

confidence: 99%

Glioma Cell Biology

Šedo¹,

Mentlein²

2014

View full text Add to dashboard Cite

“…Investigators thus studied the role of interferons a, b and c to modulate the immune system. The first clinical results among 17 patients with malignant brain tumors treated with intratumoral interferon in addition to surgery and radiation versus surgery, radiation, and chemotherapy were published in 1989; although encouraging results were reported, the design of the trial limited drawing conclusions specific for the interferon [18]. Interferon-c was of particular interest Immunotherapeutic Treatment Strategies for Primary Brain Tumors Das et al…”

Section: Evolution Of Immunotherapy Strategiesmentioning

confidence: 99%

Immunotherapeutic Treatment Strategies for Primary Brain Tumors

Das

Raizer

Muro

2008

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Primary brain tumors account for a minor fraction of cancer diagnoses made worldwide and remain one of the most difficult to treat. Despite ongoing efforts to improve the quality of life and overall survival of these patients, current multimodality therapy has achieved only modest gains; the median survival is approximately 14 months among patients with the deadliest form of primary brain tumor, glioblastoma multiforme. Although the brain has been long considered an immunologically privileged organ, there is increased awareness of and appreciation for the complex interplay between the nervous system and the immune system in the setting of many disease states, including neoplastic. Although the concept of harnessing the specificity, activity, and memory of the immune system toward the treatment of brain tumors has been in existence for several decades and the neuro-oncology literature holds many publications that once promised of a breakthrough, only recently has a strategy emerged that addresses many of the limitations identified through past failures. It is with cautious optimism that the authors review the past and discuss the present status of immunotherapy and its role in the management of patients with primary brain tumors.

show abstract

Intratumor Application of Human Leukocyte Interferon-α in Patients with Malignant Brain Tumors

Cited by 21 publications

References 0 publications

CIGB-128, as compassionate intracranial treatment in patients with non-operable or progressive high grade gliomas

CIGB-128, as compassionate intracranial treatment in patients with non-operable or progressive high grade gliomas

Glioma Cell Biology

Immunotherapeutic Treatment Strategies for Primary Brain Tumors

Contact Info

Product

Resources

About